http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110917148-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-36234 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-18434 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5254 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-18734 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-183 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-165 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-295 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-18 |
| filingDate | 2019-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-08-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-08-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-110917148-B |
| titleOfInvention | A lyophilized protective agent for MMR combined with live attenuated vaccine without gelatin and no serum albumin |
| abstract | The invention provides a freeze-dried protective agent for MMR combined with attenuated live vaccine without gelatin and no blood albumin, and belongs to the field of biological products. The final concentration of each component of the freeze-drying protective agent of the present invention per liter of semi-finished vaccine is: sucrose 30-100g/L, trehalose 10-30g/L, sodium glutamate 0.3-15g/L, urea 0-10g/L , mannitol 0-10g/L, sorbitol 0-25g/L, the matrix liquid of preparation protective agent is Earle's balanced salt solution or PBS buffer solution or water for injection, and this lyophilized protective agent does not contain gelatin and human albumin. The freeze-dried protective agent of the invention is used for preparing the freeze-dried vaccine of MMR combined with attenuated live vaccine, which can improve the stability of the combined MMR combined with attenuated vaccine in the freeze-drying process and the storage process, and can improve the effect of freeze-dried vaccine on the vaccine. Human safety, reduce adverse reactions to vaccines, and ensure that virus titers remain high after lyophilization and reconstitution. |
| priorityDate | 2019-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 60.